Allograft Anti-inflammatory Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bone graft procedures using allografts often result in an inflammatory response due to the implantation of heterogeneous material, leading to delayed integration, chronic pain, and potential rejection, especially in areas like the epiphyses where cartilage formation and integration are not properly promoted.
Innovation Solution
Incorporating anti-inflammatory compounds into allografts or applying them directly to the bone defect site, either during processing, packaging, or at the time of implantation, to reduce catabolic cytokine production and enhance the integration of allografts with host tissue, using sustained-release formulations and carriers like collagen or microspheres.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If allograft bone is used as a graft substitute, then availability and avoidance of harvesting trauma are improved, but inflammatory response and delayed integration occur
Solution Approach 1:
The patent introduces anti-inflammatory compounds as intermediary substances that mediate between the allograft material and the host immune system. These compounds act as chemical mediators that suppress the harmful inflammatory response while allowing beneficial integration processes to proceed, thereby resolving the contradiction between using allografts and avoiding rejection.
Solution Approach 2:
The patent changes the chemical and biological parameters of the graft composition by incorporating anti-inflammatory agents. This modifies the immune response parameters locally at the graft site, transforming the hostile inflammatory environment into a more favorable condition for integration without changing the fundamental allograft nature of the material.
2Loss of time
If anti-inflammatory compounds are applied to allografts, then integration speed is improved, but device complexity increases
Solution Approach 1:
The anti-inflammatory compounds are incorporated into the allograft material during manufacturing or packaging, before implantation. This preliminary action ensures that the anti-inflammatory effect is already in place when the graft is implanted, eliminating the need for separate post-implantation treatments and reducing overall treatment complexity despite the enhanced composition.
Data Source
AI summary
Methods and compositions are provided for reduction of inflammation and improved allograft/host tissue integration comprising placing at least one anti-inflammatory compound onto a site of the defect and placing a graft structure onto the site of the defect.